A psychiatrist accused of negligence in Maradona's death does not regret the treatment provided
BUENOS AIRES, Argentina (AP) — Psychiatrist Agustina Cosachov, one of the seven healthcare professionals on trial accused of negligence in the death of soccer great Diego Maradona testified on Thursday that she does not regret the treatment she provided to the former national team captain and blamed the private medical company for the deficiencies in his home care.
Maradona had surgery for a hematoma that formed between his skull and brain and stayed in intensive care at Los Olivos clinic between Nov. 4-11. He then was sent recover to a private home where he died on Nov. 25. 2020 at the age of 60.
'I acted convinced that what I was doing was best for the patient,' said the psychiatrist, the first of the defendants to testify in the courts of San Isidro, a northern suburb of Buenos Aires. 'In my role, I did what I could and even more.'
Cosachov was part of Maradona's medical team during the final stages of his life, along with neurosurgeon Leopoldo Luque and psychologist Carlos Díaz. The three are on trial with doctors Nancy Forlini and Pedro Di Spagna; Mariano Perroni, a representative of the company that provided the nursing service; and nurse Ricardo Almirón.
Maradona died in a rented house in Tigre, a northern suburb of Buenos Aires.
Cosachov broke down in tears twice during her testimony, once when the presiding judge asked her what she thought happened to Maradona, to which she responded simply: 'I don't know.'
Three judges will decide whether those charged are guilty of manslaughter. The maximum jail time for those sentenced is 25 years.
According to the prosecution, the accused professionals didn't provide adequate medical care.
'We were all in agreement for home hospitalization,' the psychiatrist stated, referring to Maradona's daughters, his sisters, his ex-wife, and the company's doctors. 'Involuntary hospitalization was also considered but the family didn't want that and home hospitalization was the only option.'
According to testimony of the director of the clinic where Maradona had surgery, the soccer star requested alcohol during the post-operative period, and was difficult to deal with.
___
AP soccer: https://apnews.com/hub/soccer
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
HCA Healthcare Foundation Awards $1 Million Grant to Educate Texas for Healthcare Career Pathways
HCA Healthcare Inc. (NYSE:HCA) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 26, HCA Healthcare announced that its HCA Healthcare Foundation, through its Healthier Tomorrow Fund, will provide a new $1 million grant to Educate Texas, which is an initiative of Communities Foundation of Texas. HCA Healthcare Foundation promotes health and well-being across all the communities HCA Healthcare serves The latest donation expands upon a previous $1.35 million grant made by the Foundation to Educate Texas in 2022. The funding aims to increase student access to programs that prepare them for careers in healthcare, specifically focusing on high schools in Texas that offer Pathways in Technology Early College High School (P-TECH) healthcare career tracks. The initial 2022 grant supported the expansion of healthcare career pathways across P-TECH campuses, growing from 20 to 104 schools and enrolling ~10,000 high school students in these specialized programs. A team of healthcare professionals in lab coats and masks meeting at a hospital ward. The new $1 million grant will enable Educate Texas to further enhance the quality of program implementation. The initiative seeks to increase the number of students earning healthcare degrees and credentials and foster greater engagement of hospital employers, including HCA Healthcare-affiliated hospitals, with school districts in North Texas, Austin, San Antonio, and the Houston Gulf Coast region. HCA Healthcare Inc. (NYSE:HCA) owns and operates hospitals and related healthcare entities in the US. While we acknowledge the potential of HCA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Jim Cramer on Hims & Hers: 'You Gotta Generate Some Discipline Here'
Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 14 stocks Jim Cramer recently shared insights on. Discussing the importance of discipline over conviction, Cramer commented: 'No matter how much you love these speculative winners, you don't have a gain until you actually ring the register. At the end of last week, for example, Hims & Hers Health, the online healthcare company, was trading at $64. But then yesterday, the stock fell 22 bucks for an almost 35% decline… What I care about is that this stock… [has] almost tripled in two months. If you owned Hims & Hers up almost 200% and you hadn't sold any at that point, you were being a knucklehead. A nurse in a telehealth platform talking with a patient on video call for consultation. Hims & Hers Health (NYSE:HIMS) operates a telehealth platform that delivers prescription and non-prescription health and wellness products. The company's products include medication, skin care, sexual health, hair care, and wellness items, supported by ongoing care from licensed healthcare professionals. While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
an hour ago
- Yahoo
Report forecasts tech-driven vision for NHS could add £40bn to annual UK GDP
With profound change in sight for the UK's National Health Service (NHS), a new report indicates that a technology-driven vision for the national health system could add £40bn ($54.8bn) to the nation's annual GDP. Co-authored by Boston Consulting Group (BCG), Siemens Healthineers, and Imperial College London, the report follows the UK Spending Review on 11 June, in which Chancellor of the Exchequer Rachel Reeves announced that the NHS will receive a £29bn ($39.1bn) funding boost, reflecting a 3% annual rise on current levels over the next three years to reach £226bn by 2029. Reeves also revealed that the funding would increase the NHS's technology budget by almost 50%, with £10bn ($13.5bn) of the total funding earmarked to bring the 'analogue health system into the digital age'. Commissioned by the NHS as input to its 10-Year Plan, which is anticipated to be released in early July, the report foresees that innovation in diagnosis has the potential to impact population outcomes through risk stratification and intervention to 'prevent disease and alleviate burden on the broader healthcare system'. According to the research, by addressing health inequalities through predictive, personalised and preventative care, two to three million healthy life years could be added to the five most economically deprived groups among the UK population each year, thereby boosting the UK's GDP by around £40bn each year. Achieving this aim would primarily be driven by implementing technologies such as AI for the early diagnosis of diseases such as cancer, the report stated. Also, the report envisions the deployment of AI and technologies including remote patient monitoring tools, to take preventative action on conditions such as high blood pressure and hypertension that are well-established predicates of life-threatening conditions such as coronary artery disease (CAD), stroke, and cancer. In turn, the report forecasts that the impact of technologies' deployment in the NHS would deliver £12bn-£18bn ($16.4-$24.7bn) in productivity gains for NHS healthcare systems annually. By integrating diagnostic data into NHS R&D, the report also forecasts that drug development timelines could be reduced, resulting in new drugs being brought to patients up to twice as fast, with operational cost savings and commercial data revenue worth £10bn-£15bn ($13.7bn- $20.5bn) to the NHS annually. Ben Horner, managing director and partner at BCG and co-author of the report, said: 'As the UK Government prepares to set out its 10-Year Health Plan, this research highlights the scale of the opportunity ahead. 'By embracing technology and data-driven innovation, the NHS could add over £40bn to UK GDP annually. This would improve patient outcomes, easing pressure on frontline services and boosting productivity across the system. The foundations are already in place; now is the moment to shift from pilots to full-scale implementation.' "Report forecasts tech-driven vision for NHS could add £40bn to annual UK GDP" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
